Medicine · Projected milestone
Zasocitinib wins FDA approval
75% by 2028 · including earlier years
The year is an editorial timing estimate. The percentage applies to occurrence by the stated deadline. These estimates are not calibrated odds.
The computationally designed psoriasis medicine gains US marketing approval after regulatory review.
Explore this milestone on the interactive mapWhat the forecast means
Milestone stage: regulatory approval
Clinical results and filing are already reported in md_aidrug; regulatory approval is the unresolved event here.
Timing window: 2027–2028. An editorial range, not a statistical confidence interval.
Completion criteria: Resolve only against a dated FDA approval letter, approved label or official FDA approval record for this drug and indication. An accepted filing, target review date or positive trial does not suffice.
This page describes a forecast, rather than an achieved result. Read the methodology and assumptions.
Built on
Led to
Sources & evidence
- Takeda: FDA accepts zasocitinib application for priority review 2026-09-14
Takeda reports FDA acceptance of its psoriasis application after positive Phase 3 results, with a target decision in Q1 2027. Zasocitinib remains investigational; acceptance for review is not approval.
- Schrödinger and Nimbus: computational design of the TYK2 inhibitor
The design collaborators describe structure-based, physics-guided FEP+ discovery and optimization. This supports computational drug design; it does not establish that generative AI alone discovered the medicine.
Record reviewed 2026-10-18